Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trelagliptin vs Vildagliptin in Type 2 Diabetes
NCT06913101Active, not recruiting
- Sponsor
- PNS Hafeez Naval Hospital
- Start
- Nov 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of trelagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by PNS Hafeez Naval Hospital. Primary endpoint: Percentage of Participants Achieving HbA1c <7% at 3 months. Started Nov 2024; status: active, not recruiting.
02
Drugs
trelagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06913101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06913101.